APABETALONE, AN EPIGENETIC BET INHIBITOR IN A PHASE 3 TRIAL, INHIBITS VASCULAR INFLAMMATION AND CELLULAR ADHESION LEADING TO BENEFICIAL OUTCOMES IN CVD PATIENTS

Authors :: Michael O. Sweeney
Sam Dorosz
Emily Daze
Laura Tsujikawa
Li Fu
Christopher Halliday
Deborah Studer
Stephanie C. Stotz
Brooke Rakai
Jan O. Johansson
Sylwia Wasiak
Kristina D. Rinker
Christopher D. Sarsons
Norman C.W. Wong
Shovon Das
Ewelina Kulikowski
Source :: Journal of the American College of Cardiology. 73:2063
Publication Year :: 2019
Publisher :: Elsevier BV, 2019.
Abstract: Apabetalone (RVX-208) is a small molecule bromodomain & extraterminal (BET) protein inhibitor, targeting the second bromodomain (BD2) of BET proteins. In cardiovascular disease (CVD) patients enrolled in phase 2 trials apabetalone treatment reduced the relative risk of a CV event by 44% (Nicholls

Subjects :: Vascular inflammation
Proteinase inhibitor
business.industry
chemical and pharmacologic phenomena
hemic and immune systems
Bromodomain
BET inhibitor
Relative risk
Cancer research
Medicine
Epigenetics
Cardiology and Cardiovascular Medicine
Cell adhesion
business

Tools